Cargando…
Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
This multicenter, prospective trial was conducted to develop an effective and safe reinduction regimen for marrow-relapsed pediatric acute lymphoblastic leukemia (ALL) by modifying the dose of idarubicin. Between 2006 and 2009, the trial accrued 44 patients, 1 to 21 years old with first marrow-relap...
Autores principales: | Koh, Kyung-Nam, Im, Ho Joon, Kim, Hyery, Kang, Hyoung Jin, Park, Kyung Duk, Shin, Hee Young, Ahn, Hyo Seop, Lee, Ji Won, Yoo, Keon Hee, Sung, Ki Woong, Koo, Hong Hoe, Lim, Young Tak, Park, Jun Eun, Park, Byung-Kiu, Park, Hyeon Jin, Seo, Jong Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334163/ https://www.ncbi.nlm.nih.gov/pubmed/28244291 http://dx.doi.org/10.3346/jkms.2017.32.4.642 |
Ejemplares similares
-
Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia
por: Yoon, Jong Hyung, et al.
Publicado: (2009) -
APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia
por: Kim, Hyery, et al.
Publicado: (2018) -
Treatment outcomes in children with Burkitt lymphoma and L3 acute lymphoblastic leukemia treated using the lymphoma malignancy B protocol at a single institution
por: Park, Eun Sil, et al.
Publicado: (2011) -
Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents
por: Kim, Hyery, et al.
Publicado: (2014) -
Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
por: Kim, Hyery, et al.
Publicado: (2012)